Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We deserve a break. Europe, lift the hold...something.... This talk about Sid gave me concern.
SA really attempts to provide good reporting based on solid research with lots of disclaimers of author and reveals if they have long positions etc, IT SEEMS.I think they realize guys like you read it who are not stupid and would not read at all, if propaganda. But like anything, you have the good and the bad. authors. I think with guys like Hov, they lean good.
Trade,
Thanks for research. This board keeps it real. Somebody knows something and we are due for a break.
ADXS in terms of science, trials, and partners looks so solid. And we are diversified in our treatments.
So due, and we have survived a lot of hits.... in fact I will call it bad luck. Good luck is coming. I am still puzzled about Ken Berlin, is there some reason he was picked that we don't know about?
Europe, positive news on canine, and hold lifted....should be notable positives for PPS...I am optimistic
Tons of Good Prospective things in pipeline. ADXS should walk tall and PPS up. Amgen is a supporter and more. Lift that one hold. Just wish it was all not so slow. We have more trials going on than most is my bet. PETX needs to give us some testimonial from doggyworld.
So if Black Rock bought 650K shares, then where is our price jump? They upped their holdings by 28%.
I say good news.
I am tired of the whining. I am glad to be out of Limbo with Lombardo and CMO....all we can do is give them a chance and BE POSITIVE! OUR SCIENCE ROCKS, ALWAYS HAS AND WILL PROVE ITSELF. Keep your eye on the keyhole and not the doorknob.....
What was the conversation? How do you feel about things James otherwise?
We want ADXS stock price to go up, right? So...don't be counterproductive folks. And guessing on this board always reminds me of what guessing is. A good hypothesis works better.
Amgen+ -Cash Flow Anyone have any guesses what money might be coming in from deals we already have? Sorry I asked this a long time ago. Always worried about cash....;(
Can you remind me of link or who is
That clinical trial hold hurt, but I think it might be AZ, plus many patients have many issues beyond cancer in trials. We just get nailed hard for anything, good news seems ignored. This 3/20 Alpha seemed real enough.
https://seekingalpha.com/instablog/1058124-terry-chrisomalis/5128660-advaxis-receives-fda-clinical-hold-creates-buying-opportunity
ADXS being picked on by shorts...? they love waiting periods...any suggestions of ADXS enemies....is that what I am reading from your post... Biotechs seem easy short targets in general.
Testimonial PR..saving Dog lives....not the hugest market, but one of our first big landmark successes.
Thanks Bourbon, Go AMGEN/ ADXS! I recall mixed reviews on Denner.......
Good things will come. I said this years ago and it still holds true "Patience Pays" ADXS is a game of patience for sure. 2018 should prove big, but 2 yrs even more. As much as the funding was not well planned in terms of timing, it is good to know we are not desperate for cash.
ADXS prepared to go it alone for quite awhile. I am banking on them like so many of us. At least not being held hostage by shorts or depending on a buyout. 2018 has a big pipeline of events. Buckle up!
The hold should clear out more shorts....we need that explained. I bet it is AZ problem.
Summary: ADXS has enough cash to ride through ups/downs and get through MAJOR milestones in next 12 months. Not desperate, does not require caving in to bad deals from sharks. Agree?
Just read transcript of earnings call. Busy company, so much going on. Eggs not in one basket for sure. I like how Tony shut down the guy about ADXS NEO. Hard to believe only 4 questions.
We are in a waiting game...just want to be here when news hits. Europe first.
Joche90, I am curious about your opinions on Europe and Advaxis 2018 Pipeline, the presentation showed an impressive timeline. It closed on that 8 mill share day last week....
You want to be here when EU approval happens!
ADXS has not sold out, but self financing the bulk of cash load. No sellout yet, self financing, more risk, more reward. I think so much positive on science, that when we break through, our reward will come.
Presentation, while a marketing tool is impressive.
https://www.advaxis.com/wp-content/uploads/2018/02/February-2018-Corporate-Presentation-Final.pdf
Painful right now, but I am keeping faith....based on on all the facts we have in hand..
ADXS-PSA Metastatic Prostate Ph1/2 Combination with pembrolizumab Part
A Monotherapy
Completed
Axalimogene
filolisbac
Persistent Recurrent / Metastatic Cervical Cancer (PRmCC) EU
Conditional Approval Filing Completed
Axalimogene 2018
filolisbac
ADVANCE Metastatic Cervical Ph 3 Combination with
nivolumab Trial Initiation
ADXS-NEO Ph 1 Initiation 1H 2018
ADXS-PSA Metastatic Prostate Ph1/2 Combination with pembrolizumab Part 2018
B Monotherapy Combination Therapy Data
Axalimogene 2018
filolisbac
Announce planned IST in Head and Neck
ADXS-HOT 2018
Multiple IND Filings
First in Human – 1 Tumor Type 2018
and of course
Axalimogene
filolisbac
Metastatic Cervical Ph 1/2 Combo with durvalumab
Part 1 Combination Therapy: Dose Escalation, Dose Determination Completed
Part B Expansion Interim Readout 2019
Well put, they could not beat the clock. Europe took (is taking) too long and PETX while a good deal and noteworthy, did not put money in the bank. The biotech slow clock takes lots of cash and patience. They said no dilution necessary, but that is gambling against the clock. We will win over time, our science is too good.
Another words, the worst is over ;(
8 million plus shares yesterday, do you think there was any institutional play going on or just shorts unloading?
Fair enough, at the same time "somebody" is get a screaming deal at these prices. If "somebody" thinks a good chance of EU approval, then they are cashing in major. "Somebody" knows something we don't is my bet... Illegal? I guess EU is common knowledge. We should all be buy more, but I am already so in.....I could use the average down though.
Maybe it already happened 8 mill plus share volume...
I would buy today, if I could. Something is cooking. New CEO getting bargain shares? Why issue at rock bottom price...what is incentive? 20 mill is so low. A secret is being kept.
I feel "swim" Let's keep some faith. Our science is solid.
I wish we knew how much cash inflows were in the pipeline vs. the prospect of dilution. Cash inflows preferred ;) Amgen due, I believe.
Joche90 for Advaxis CEO!
Was DOC worth $58 million? Maximize stock price is the job. Hard to justify....
http://insiders.morningstar.com/trading/executive-compensation.action?t=ADXS®ion=usa&culture=en-US
Try rule 144, restricted shares
I I could not agree more ??????. Too bad they could not squelch the overcompensation of shares issue BEFORE it got ugly. FBG got what he wanted. Stock has tanked ever since his departure.
Take 2:
Phase II Cervical- SP should be reacting much more positively:
Quote:
It was noted that the primary endpoint was the 12-month overall survival rate for women who took axalimogene filolisbac. It was shown that 19 out of 50 patients or 38% of patients were alive past the 12-month time point. Why is this rate significant? That's because it was a 55% improvement over the typical expected 12-month survival rate in this patient population of 24.5%. Another thing to point out is that at least 50% of patients recruited into the study had received more than one prior therapy before being recruited. One such treatment given as a prior therapy was with bevacizumab, which is marketed as Avastin. That's a huge feat, because Avastin is marketed by Roche (OTCQX:RHHBY). The fact that axalimogene filolisbac achieved what Avastin couldn't in allowing patients to respond to therapy is remarkable.
Phase II Cervical- SP should be reacting much more positively:
Jame, this hat is a wow! Everyone on this MB may be near someone who may be able to access AIM2SERV. I wonder how long it takes to screen and complete recruiting. Big Demand I bet.
I got my call, no on stock authorization and no on employee stock option, yes the rest.
We have some good news on Europe and still down today...Shorts BS! I actually have even more stock.
"Data supports its planned submission of a conditional Marketing Authorization Application with the European Medicines Agency for axalimogene filolisbac for the treatment for metastatic cervical cancer"!!